Betoptic S Shortage Update: What Patients Need to Know in 2026

If you've been having trouble filling your Betoptic S prescription in 2026, you're asking a very reasonable question: is there an official shortage? The answer is nuanced — and understanding the full picture can help you take better action.

Current Betoptic S Availability Status (2026)

As of 2026, Betoptic S (betaxolol hydrochloride ophthalmic suspension 0.25%) does not appear on the FDA's official drug shortage database. However, patients and pharmacists across the country continue to report difficulty locating it at retail pharmacies. This is an important distinction: a drug can be genuinely hard to access without being in a formally declared shortage.

The FDA's shortage list primarily tracks manufacturing-level disruptions that affect nationwide supply. Regional distribution gaps, stocking decisions by individual pharmacies, and insurance-driven access barriers don't typically trigger a formal shortage declaration — yet they affect real patients every day.

What Is Causing Supply Gaps for Betoptic S?

Several overlapping factors contribute to Betoptic S availability problems in 2026:

• Brand-only product. There is no FDA-approved generic version of the Betoptic S suspension form. Without generic competition, Novartis controls all supply, and pharmacies stock less of it because of high cost and limited turnover.
• Complex manufacturing. Betoptic S uses a proprietary resin suspension system that is more technically complex to produce than a simple ophthalmic solution. Manufacturing delays or batch issues can quickly create regional shortages.
• High cost discourages stocking. At $400–$521 per 10 mL bottle, pharmacies have little incentive to carry inventory they don't know they'll sell. They typically order on demand rather than proactively.
• Insurance restrictions. Many plans require prior authorization or step therapy before covering Betoptic S, reducing the number of filled prescriptions — which in turn reduces pharmacy stock levels.

Historical Context: Has Betoptic S Been in Short Supply Before?

Betoptic S has had a long history of intermittent availability challenges. The drug was first approved by the FDA in 1985, making it one of the earlier ophthalmic beta blockers on the market. Over the decades, as newer glaucoma drugs — particularly prostaglandin analogs like latanoprost — became the standard of care, the prescription volume for Betoptic S declined. Lower demand means manufacturers have less incentive to maintain robust supply buffers, making the drug more susceptible to localized shortages.

Why Betoptic S Still Matters Despite Newer Alternatives

Betoptic S occupies an important clinical niche. Its cardioselective profile means it blocks only beta-1 receptors, making it safer for patients with reactive airway disease (asthma, COPD) who cannot tolerate nonselective beta blockers like timolol. For these patients, betaxolol may be the only beta blocker that's medically appropriate — and the suspension formulation causes significantly less ocular discomfort than the original solution.

What Should Patients Do Right Now?

If you're having trouble finding Betoptic S, here are the most important steps:

1. Search pharmacies near you. Use medfinder to locate which pharmacies in your area have it in stock without spending hours on the phone.
2. Don't skip doses. Contact your ophthalmologist immediately if you're running low. They can authorize a temporary alternative to keep your IOP controlled.
3. Ask about the Novartis Patient Assistance Foundation. Uninsured or underinsured patients with limited income may qualify to receive Betoptic S at no cost through the Novartis Patient Assistance Foundation (1-800-277-2254).
4. Request a prior authorization appeal. If your insurer is blocking coverage, ask your doctor to file a medical necessity exception — especially if you have a clinical reason (like asthma) for needing the suspension over generic alternatives.

Monitoring the Situation

We recommend keeping communication open with your ophthalmologist and pharmacist about ongoing access to Betoptic S. If availability becomes consistently problematic in your area, your doctor may recommend transitioning to a long-term alternative. See our guide to Betoptic S alternatives for a full comparison of options.